Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. DiscussionsWILHELM, Scott M; ROBINSON, Ann V; KRISHNAMURTHI, Smitha S et al.Surgery. 2007, Vol 142, Num 4, pp 581-587, issn 0039-6060, 7 p.Article

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumorsBRELL, Joanna M; KRISHNAMURTHI, Smitha S; RATH, Linda et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 4, pp 547-553, issn 0344-5704, 7 p.Article

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersLORUSSO, Patricia M; KRISHNAMURTHI, Smitha S; RICART, Alejandro D et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1924-1937, issn 1078-0432, 14 p.Article

The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinasesEL-KHOUEIRY, Anthony; POSEY, James A; CASTILLO FERRANDO, Juan Ramón et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 53-64, issn 0344-5704, 12 p.Article

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabineKRISHNAMURTHI, Smitha S; BRELL, Joanna M; COONEY, Matthew M et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 3, pp 441-450, issn 0344-5704, 10 p.Article

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabKHAMBATA-FORD, Shirin; GARRETT, Christopher R; TAN, Benjamin R et al.Journal of clinical oncology. 2007, Vol 25, Num 22, pp 3230-3237, issn 0732-183X, 8 p.Article

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid TumorsDAUD, Adil I; KRISHNAMURTHI, Smitha S; BARDY-BOUXIN, Nathalie et al.Clinical cancer research (Print). 2012, Vol 18, Num 4, pp 1092-1100, issn 1078-0432, 9 p.Article

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaBRELL, Joanna M; KRISHNAMURTHI, Smitha S; IVY, S. Percy et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 851-857, issn 0344-5704, 7 p.Article